Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases

Øverstad, Siri; Tjønnfjord, Eirik; Garabet, Lamya; Fronas, Synne G.; Bergan, Jonas; Aballi, Saad; Ghanima, Waleed

doi:10.1016/j.thromres.2020.06.032

Cited by 27 publications

(41 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] Increased thromboembolic events were also documented with the SARS, MERS, and influenza A H1N1 viruses. [76][77][78][79][80][81] The true risk of VTE in patients with COVID-19 is difficult to determine since no placebo-controlled randomized trials have been conducted. Rates of VTE in general medical ward patients with COVID-19 have been reported to be around 4% in clinically evaluated patients and as high as almost 15% in patients screened with CUS (Table 3).…”

Section: Risk Of Vtementioning

confidence: 99%

“…Risk assessment should be performed with symptomatic patients with COVID-19 treated at home, since a number of them may still have several VTE risk factors, including immobility, and are at risk of thromboembolic events. 52,[79][80][81] Support for the paradigm that a higher intensity of anticoagulation than standard prophylactic doses of heparin comes from previously published evidence from the H1N1 influenza pandemic in 2009. 82 An observational cohort study of critically ill patients with severe ARDS from H1N1 viral pneumonia demonstrated that empiric systemic heparinization titrated to a goal heparin level of 0.3 -0.7 anti-Xa units/mL was significantly better at reducing VTE rates than standard prophylactic doses of either UFH or LMWH.…”

Section: Accepted Articlementioning

confidence: 99%

“…A number of studies have reported a higher rate of VTE than would be expected in general ward and ICU patients with COVID‐19 (Table 3). 29–44 Increased thromboembolic events were also documented with the SARS, MERS, and influenza A H1N1 viruses 76–81 . The true risk of VTE in patients with COVID‐19 is difficult to determine since no placebo‐controlled randomized trials have been conducted.…”

Section: Risk Of Vtementioning

confidence: 99%

“… 31–41, 43, 44 Consequentially, all hospitalized patients with COVID‐19 should receive pharmacologic VTE prophylaxis regardless of any risk assessment predictors unless the risk of bleeding is considered high. Risk assessment should be performed with symptomatic patients with COVID‐19 treated at home, since a number of them may still have several VTE risk factors, including immobility, and are at risk of thromboembolic events 52, 79–81 …”

Section: Prevention Of Vtementioning

confidence: 99%

See 3 more Smart Citations

Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID‐19

Dobesh

Trujillo

2020

Pharmacotherapy

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)has led to a worldwide pandemic, and patients with the infection are referred to as having COVID-19. Although COVID-19 is commonly considered a respiratory disease, there is clearly a thrombotic potential that was not expected. The pathophysiology of the disease and subsequent coagulopathy produce an inflammatory, hypercoagulable, and hypofibrinolytic state. Several observational studies have demonstrated surprisingly high rates of venous thromboembolism (VTE) in both general ward and intensive care patients with COVID-19. Many of these observational studies demonstrate high rates of VTE despite patients being on standard, or even higher intensity, pharmacologic VTE prophylaxis. Fibrinolytic therapy has also been used in patients with acute respiratory distress syndrome. Unfortunately, high quality randomized controlled trials are lacking. A literature search was performed to provide the most up-to-date information on the pathophysiology, coagulopathy, risk of VTE, and prevention and treatment of VTE in patients with COVID-19. These topics are reviewed in detail, along with practical issues of anticoagulant selection and duration. Although a number of international organizations have produced guideline or consensus statements, they do not all cover the same issues regarding anticoagulant therapy for patients with COVID-19, and they do not all agree. These statements and the most recent literature are combined into a list of clinical considerations that clinicians can use for the prevention and treatment of VTE in patients with COVID-19.

show abstract

Section: Risk Of Vtementioning

confidence: 99%

Section: Accepted Articlementioning

confidence: 99%

Section: Risk Of Vtementioning

confidence: 99%

Section: Prevention Of Vtementioning

confidence: 99%

See 2 more Smart Citations

Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID‐19

Dobesh

Trujillo

2020

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…10 av pasientene med hjerteaffeksjon (59 %) hadde kronisk hjertesykdom. Fire pasienter (6 %) utviklet tromboemboli; to av disse er rapportert i en tidligere artikkel (17). Delir eller konfusjon var ikke en del av de predefinerte komplikasjonene i registeret.…”

unclassified

70 pasienter med covid-19 innlagt ved Sykehuset Østfold

Øverstad¹,

Tjønnfjord²,

Olsen³

et al. 2020

Tidsskriftet

Self Cite

View full text Add to dashboard Cite

How we approach thrombosis risk in children with COVID‐19 infection and MIS‐C

Sharathkumar

Faustino

Takemoto

2021

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Thrombosis within the microvasculature and medium to large vessels is a serious and common complication among critically ill individuals with coronavirus disease 2019 . While children are markedly less likely to develop severe disease than adults, they remain at risk for thrombosis during acute infection and with the postacute inflammatory illness termed multisystem inflammatory syndrome in children.Significant knowledge deficits in understanding COVID-19-associated coagulopathy and thrombotic risk pose clinical challenges for pediatric providers who must incorporate expert opinion and personal experience to manage individual patients. We discuss clinical scenarios to provide framework for characterizing thrombosis risk and thromboprophylaxis in children with

show abstract

Venous thromboembolism and coronavirus disease 2019 in an ambulatory care setting - A report of 4 cases

Cited by 27 publications

References 10 publications

Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID‐19

Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID‐19

70 pasienter med covid-19 innlagt ved Sykehuset Østfold

How we approach thrombosis risk in children with COVID‐19 infection and MIS‐C

Contact Info

Product

Resources

About